The Antitumor Role of Incomptine A in a Breast Cancer Murine Model: Impairment of Hexokinase II Expression and Apoptosis Induction
Authors:
- Angel Giovanni Arietta-GarcíaAngel Giovanni Arietta-García
- Fernando CalzadaFernando Calzada
- Antonio Franco-VadilloAFAntonio Franco-Vadillo
- Irais Monserrat Barrientos-BuendíaIBIrais Monserrat Barrientos-Buendía
- Francisco Javier Alarcón-AguilarFAFrancisco Javier Alarcón-Aguilar
- Elihú BautistaElihú Bautista
- Paola Santana-SánchezPSPaola Santana-Sánchez
- Israel Ramírez-SánchezIRIsrael Ramírez-Sánchez
- Rosa María Ordoñez-RazoRosa María Ordoñez-Razo
Open Access
Abstract
Breast cancer (BC) is the most common type of cancer in women worldwide. Hexokinase II (HKII) overexpression is associated with the proliferation and survival of tumor cells, as it inhibits apoptosis. Incomptine A (IA) is cytotoxic to breast cancer cells, likely due to a decrease in the expression of HKII. This study evaluated the antitumor activity of IA in an in vivo mouse model of BC. A model was generated from 4T1 cells and grouped tumor-bearing animals according to treatment: in IA or doxorubicin (DOXO), or untreated (UT). Comparing the body weight and tumor size between groups, tumors were analyzed using histopathological, Western blot, flow cytometry, and mitochondrial activity assays. Tumors IA-treated showed a reduction in size, weight, and number of tumor cells; the expression of HKII and Bcl-2 decreased, while that of Caspase-3 increased. IA treatment increased apoptosis and reduced mitochondrial activity in tumor cells. This data showed that IA has an impact on tumor cells by reducing tumor volume and size, increasing cell apoptosis, and decreasing mitochondrial activity, all of which could be attributed to reduced HKII expression. Therefore, IA may be a promising compound that requires further studies to elucidate its mechanism of action and analyze its possible future use in BC.Keywords
Funding Information
- Financiamiento para la Investigación Científica y Desarrollo Tecnológico en Salud, Instituto Mexicano del Seguro Social (R-2023-3603-015)
This publication has 37 references indexed in Scilit:
- Parthenolide as a potential therapeutic agent for gastric cancer: Exploring oxidative stress and DNA damagePharmacological Research - Modern Chinese Medicine, 2024
- Deoxyelephantopin, a germacrane‐type sesquiterpene lactone from Elephantopus scaber, induces mitochondrial apoptosis of hepatocarcinoma cells by targeting Hsp90α in vitro and in vivoPhytotherapy Research, 2022
- ‘Sugarcoating’ 2-deoxyglucose: mechanisms that suppress its toxic effectsCurrent Genetics, 2020
- New molecular and biochemical insights of doxorubicin-induced hepatotoxicityLife Sciences, 2020
- In silico construction of HK2-VDAC1 complex and investigating the HK2 binding-induced molecular gating mechanism of VDAC1Mitochondrion, 2016
- Adverse breast cancer treatment effects: the economic case for making rehabilitative programs standard of careSupportive Care in Cancer, 2014
- A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2012
- Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignanciesThe Prostate, 2010
- In vitro and in vivo antiproliferative activity of laherradurin and cherimolin‐2 of annona diversifolia saffPhytotherapy Research, 2009
- Mouse 4T1 Breast Tumor ModelCurrent Protocols in Immunology, 2000